IGF-1 Level of 49 µg/L in a 15-Month-Old Toddler
An IGF-1 level of 49 µg/L (49 ng/mL) in a 15-month-old toddler has limited clinical utility and should not be used to determine normalcy, as IGF-1 is unreliable for assessment in children under 18 months of age. 1
Why IGF-1 Cannot Be Interpreted at This Age
The most recent pediatric endocrinology guidelines explicitly state that IGF-1 levels have limited utility within the first 18 months of life because they are significantly impacted by multiple non-pathological factors 1:
- Weight gain and adiposity status
- Type of feeding (breast milk vs. formula)
- Maternal smoking exposure
- Nutritional status
These confounding variables make it impossible to establish whether a given IGF-1 value represents normal physiology or pathology in this age group.
What Should Be Used Instead
For children up to 3 years of age, IGFBP-3 (IGF Binding Protein-3) levels are a better screening biomarker than IGF-1 1. If growth hormone deficiency is suspected in a toddler this age, the diagnostic approach should include:
- IGFBP-3 measurement rather than relying on IGF-1
- Auxologic assessment: Growth velocity, height/length tracking on growth charts, comparison to mid-parental height
- Bone age assessment if growth failure is present
- Random GH level (if under 28 days old, a level ≤5 µg/L plus other pituitary hormone deficiencies is diagnostic) 1
Reference Data Context
While research studies have measured IGF-1 in healthy toddlers 2, 3, showing mean values around 75.9 ± 36.1 ng/mL at 12 months 2, these population-based reference ranges cannot be applied clinically to individual patients under 18 months due to the high inter-individual variability from the confounding factors mentioned above.
Clinical Pitfall to Avoid
Do not attempt to diagnose or exclude growth hormone deficiency based on IGF-1 alone in a 15-month-old child. The guideline evidence is clear that this biomarker lacks specificity and sensitivity in this age group 1. If there are clinical concerns about growth, proceed with IGFBP-3 testing and comprehensive auxologic evaluation rather than interpreting this IGF-1 value.